Bone Cancer

BONE CANCER ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

Vaping Injuries Raise New Concerns About Medical Marijuana

Many recent vaping injuries have been linked to e-cigarette use of THC oils or other cannabis oil products, raising new concerns about patients with cancer who use the devices for medical marijuana.
ASCO Opinion Poll: Americans’ Knowledge About Cancer

The results of a recent ASCO poll suggest that many adults are unsure how to reduce their cancer risk and do not know what sources of information to trust.
Tools for Assessing, Managing Elderly With Cancer for Malnutrition

This review discusses nutritional interventions and management of nutritional status in elderly patients with cancer.
Nivolumab Plus Ipilimumab in Advanced Melanoma Improves Survival at 5-Year Follow-Up — but Significant Toxicities Linger

A phase 3 trial looking at nivolumab and ipilimumab in advanced melanoma has reported increased survival with the combination, but notable toxicities.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma

Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.

BONE CANCER NEWS

A recent article is only the latest in a series of studies drawing attention to the importance of di

FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma

May 2, 2018

Cancer of Unknown Origin: A Diagnostic and Treatment Dilemma

CTA Treatment Regimen Chart for Bone Cancer Updated

August 9, 2016

Pacritinib induced significant and sustained spleen volume reduction and symptom control in patients

Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma

July 12, 2016

Denosumab has robust clinical efficacy in the treatment of patients with giant cell tumor of bone.

In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy

July 24, 2015

Pacritinib induced significant and sustained spleen volume reduction and symptom control in patients

Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis

May 31, 2015

Next post in General Oncology

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exce

Female Representation on NCCN Guideline Panels Suggests Low Gender Bias